Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
March 03 2020 - 6:30AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the
“Company”) today announced that it will release its fourth quarter
and full year 2019 financial results on Thursday, March 5, 2020,
after the markets close. Aurinia’s management team will host a
conference call to discuss the Company’s financial results and to
provide a general business update.
The conference call and webcast is scheduled for March 5, 2020
at 4:30 p.m. ET / 1:30 p.m. PT. In order to participate in the
conference call, please dial +1-877-407-9170 (Toll-free U.S. &
Canada). An audio webcast can be accessed under "News/Events”
through the “Investors” section of the Aurinia corporate website at
www.auriniapharma.com. A replay of the webcast will be available on
Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a late clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are impacted
by diseases with a high unmet medical need. The Company is
currently developing an investigational drug, voclosporin, for the
treatment of lupus nephritis, focal segmental glomerulosclerosis
and dry eye syndrome. The Company’s head office is in Victoria,
British Columbia and focuses its development efforts globally. For
further information, see our website at www.auriniapharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200303005387/en/
Investor & Media Contact: Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Sep 2023 to Sep 2024